Strategies and outcomes of patients with severely reduced ejection fraction (≤15%) undergoing transvenous lead extraction: A single-center experience

Patients with severely reduced ejection fraction (SREF ≤15%) are deferred from transvenous lead extraction (TLE) owing to fear of intraoperative hemodynamic collapse. When these patients require lead extraction, their management options are limited, and they suffer from high morbidity and mortality. Left ventricular (LV) assist devices provide intraoperative hemodynamic support and facilitate TLE, enabling lifesaving interventions.

We present our experience of performing TLE in 245 patients with SREF. Additionally, we report outcomes of 8 patients who received LV support during TLE.

Between January 2008 and January 2022, we performed TLE in 245 patients with stage D heart failure, SREF, and class I or II indications for extraction. Primary (clinical success and in-hospital mortality) and secondary (length of stay and procedure-associated complications) outcomes were compared between patients with SREF and patients in our registry undergoing extraction with EF < 15%. A subgroup analysis was performed in the SREF group to evaluate outcomes of 8 patients who underwent extraction with LV assist devices.

In patients with SREF, clinical success was high (97.6%) and mortality was low (5.3%). There were no statistically significant differences in primary outcomes between groups. Similarly, there were no significant differences in procedural complications between groups. In the SREF group, there were no significant differences in outcomes between the 8 patients undergoing TLE with LV assist devices and patients that did use LV assist devices.

Lead extraction in patients with SREF can be performed safely and effectively. Adopting a few simple steps, including the early initiation of LV support, can overcome myocardial impairment in patients who decompensate.